Abstract:Human and murine brains retain discrete populations of micro RNA (miRNA) species that support homeostatic brain gene expression functions, and specific miRNA abundances are significantly and progressively altered in neurological disorders such as Alzheimer disease (AD), prion disease (PrD) and transgenic AD (Tg-AD) murine models when compared to age-matched controls. The innate-immune and pro-inflammatory, NF-kB-regulated 22-nucleotide single-stranded miRNA-146a is significantly up-regulated in parallel with the development of AD and PrD and with the onset of amyloidogenesis in several Tg-AD murine models. Here for the first time we provide evidence of significant up-regulation of miRNA-146a in amyloid-and-cytokine-stressed human neuronal-glial cells in primary co-culture and in the brains of 5xFAD mice [Tg(APPSwFlLon,PSEN1*M146L *L286V)6799Vas] which bear 5 (APP695+PSEN1) mutations that strongly drive the generation of Aβ42 peptides. AAV-miRNA vectors, microRNA analysis, 5xFAD Tg-AD models, RNA sequencing, RT-PCR, LED-Northern, microfluidic and bioinformatics technologies. Using stereotactic bilateral hippocampal injection of a scrambled AAV-miRNA-146a vector into 5xFAD brains as a baseline, selective AAV-miRNA-146a sponging vectors delivered into the hippocampus of 5xFAD mice exhibited (i) decreases in host miRNA-146a expression; (ii) increases in expression of the complement control glycoprotein complement factor H (CFH); (iii) decreases in BACE1, sAPPβsw and the generation of Aβ42 peptides; (iv) decreases in the expression of inflammatory and microglial markers including cyclooxygenase-2 (COX-2), glial fibrillary acidic protein (GFAP) and Iba1; (v) increased expression of the synaptic markers SYN1 and NR2B; and (vi) a significant improvement in cognitive performance in maze tests (NOR and Y-maze). Collectively, the results suggest that the implementation of a novel therapeutic strategy involving the sponging of miRNA-146a and related pro-inflammatory, pathogenic miRNAs may be useful in the effective treatment of AD and other progressive, age-related neurological disorders. Support: Research on miRNA in the Lukiw laboratory involving the innate-immune response in AD, AMD and in other forms of neurological or retinal disease, amyloidogenesis and neuro-inflammation was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and grants from the NIH NEI and NIA.

Intrathecal AAV9-Neprilysin Protects Against Perivascular Amyloid-β Accumulation in a Mouse Model of Cerebral Amyloid Angiopathy

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model

Lentivirus-Mediated Expression of Human Secreted Amyloid Precursor Protein-Alpha Promotes Long-Term Induction of Neuroprotective Genes and Pathways in a Mouse Model of Alzheimer's Disease

Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS

RESEARCH ON THE NEUROPROTECTIVE EFFECT OF AD WITH THE RECOMBINANT ADENO-ASSOCIATED VIRUS SYSTEM FUSING WITH ABAD-DP

Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.

Intranasal Delivery of 9-Cis Retinoic Acid Reduces Beta-Amyloid Deposition Via Inhibiting Astrocyte-Mediated Inflammation

Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders

Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice

Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice

Angiotensin-(1–7) Analogue AVE0991 Modulates Astrocyte-Mediated Neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 Pathway and Offers Neuroprotection in a Transgenic Mouse Model of Alzheimer’s Disease

Liver-specific adiponectin gene therapy suppresses microglial NLRP3-inflammasome activation for treating Alzheimer's disease

Neprilysin Protects Neurons Against Aβ Peptide Toxicity

Neprilysin: an Enzyme Candidate to Slow the Progression of Alzheimer'S Disease

Intracisternal Injection of Beta-Amyloid Seeds Promotes Cerebral Amyloid Angiopathy

Sponging of mirna-146a using aav-anti-mirna-146a-vectors mediates synaptic and amyloidogenic neuropathology and cognitive deficits in a 5xfad murine model of alzheimer’s disease

Protective effects of intrathecal injection of AAV9-RabGGTB-GFP+ in SOD1G93A mice

AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice

Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer's Disease

Pharmacological Inhibition of the Asparaginyl Endopeptidase (AEP) in an Alzheimer's Disease Model Improves the Survival and Efficacy of Transplanted Neural Stem Cells